The PIONEER AF-PCI was the first to study this scenario and randomized 2124 patients with non-valvular AF who had undergone PCI with stenting to receive, in a 1:1:1 ratio, low-dose rivaroxaban (15 mg o.d.)plus a P2Y12 inhibitor (and no ASA), very-low-dose rivaroxaban (2.5 mg b.i.d.)plus DAPT, or standard therapy with a dose-adjusted VKA plus DAPT. The gene discussed is P2RY12; the disease is atrial fibrillation.